Coherus Oncology (CHRS) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $300000.0.
- Coherus Oncology's Accumulated Depreciation & Amortization fell 2500.0% to $300000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $300000.0, marking a year-over-year decrease of 2500.0%. This contributed to the annual value of $1.8 million for FY2024, which is 4375.0% down from last year.
- Coherus Oncology's Accumulated Depreciation & Amortization amounted to $300000.0 in Q3 2025, which was down 2500.0% from $300000.0 recorded in Q2 2025.
- In the past 5 years, Coherus Oncology's Accumulated Depreciation & Amortization registered a high of $19.0 million during Q3 2021, and its lowest value of $300000.0 during Q2 2025.
- Over the past 5 years, Coherus Oncology's median Accumulated Depreciation & Amortization value was $900000.0 (recorded in 2022), while the average stood at $4.8 million.
- Per our database at Business Quant, Coherus Oncology's Accumulated Depreciation & Amortization skyrocketed by 1998.74% in 2021 and then plummeted by 9527.36% in 2022.
- Over the past 5 years, Coherus Oncology's Accumulated Depreciation & Amortization (Quarter) stood at $3.5 million in 2021, then rose by 2.86% to $3.6 million in 2022, then dropped by 11.11% to $3.2 million in 2023, then crashed by 43.75% to $1.8 million in 2024, then plummeted by 83.33% to $300000.0 in 2025.
- Its Accumulated Depreciation & Amortization stands at $300000.0 for Q3 2025, versus $300000.0 for Q2 2025 and $400000.0 for Q1 2025.